12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Javlor vinflunine regulatory update

The U.K.'s NICE issued a second final appraisal determination (FAD) recommending against the use of Javlor vinflunine from Pierre Fabre to treat advanced or metastatic transitional cell carcinoma of the urothelial tract that has progressed following prior treatment - its approved indication. The agency said the most plausible incremental cost-effectiveness...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >